Trial Profile
Randomized, double blind, placebo-controlled study investigating safety and efficacy of AL-335 in treatment naïve, chronic hepatitis C genotype 1-6 patients
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 May 2016
Price :
$35
*
At a glance
- Drugs Adafosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 16 May 2016 New trial record
- 17 Apr 2016 Results presented at The International Liver Congress™ 2016.